Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, Chambost H, Kurnik K, Liesner R, Petrini P, Platokouki H, Altisent C, Oldenburg J, Nolan B, Garrido RP, Mancuso ME, Rafowicz A, Williams M, Clausen N, Middelburg RA, Ljung R, van der Bom JG; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group. Gouw SC, et al. Among authors: carcao m. Blood. 2013 May 16;121(20):4046-55. doi: 10.1182/blood-2012-09-457036. Epub 2013 Apr 3. Blood. 2013. PMID: 23553768 Free article.
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience.
Carcao M, St Louis J, Poon MC, Grunebaum E, Lacroix S, Stain AM, Blanchette VS, Rivard GE; Inhibitor Subcommittee of Association of Hemophilia Clinic Directors of Canada. Carcao M, et al. Haemophilia. 2006 Jan;12(1):7-18. doi: 10.1111/j.1365-2516.2005.01170.x. Haemophilia. 2006. PMID: 16409170
A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
Rubinger M, Lillicrap D, Rivard GE, Teitel J, Carcao M, Hensman C, Walker I; Association of Hemophilia Clinic Directors of Canada. Rubinger M, et al. Among authors: carcao m. Haemophilia. 2008 Mar;14(2):281-6. doi: 10.1111/j.1365-2516.2007.01634.x. Epub 2008 Jan 8. Haemophilia. 2008. PMID: 18194308
Factor VIII products and inhibitor development in severe hemophilia A.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM; PedNet and RODIN Study Group. Gouw SC, et al. N Engl J Med. 2013 Jan 17;368(3):231-9. doi: 10.1056/NEJMoa1208024. N Engl J Med. 2013. PMID: 23323899 Free article.
Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010.
Vézina C, Carcao M, Infante-Rivard C, Lillicrap D, Stain AM, Paradis E, Teitel J, Rivard GE; Association of Hemophilia Clinic Directors of Canada and of the Canadian Association of Nurses in Hemophilia Care. Vézina C, et al. Among authors: carcao m. Haemophilia. 2014 Nov;20(6):771-6. doi: 10.1111/hae.12479. Epub 2014 Jul 17. Haemophilia. 2014. PMID: 25039669
190 results